

如何监测药物研发状态的最新变化

例)

监测药物研发状态的新闻变化

Drug Phase Changes  Alert  Help

44 phase changes have occurred since 11-MAR-2009

Results [1-10] [11-20] [21-30] [31-40] [41-44]

Phase 2 Clinical
[fostamatinib](#)
 Therapy Area: Peripheral T-cell lymphoma

[noscapine \(cancer\), Cougar](#)
 Therapy Area: Multiple myeloma

[ProtoCure](#)
 Therapy Area: Psoriasis

[VCH-759](#)
 Therapy Area: Hepatitis C virus infection

Pre-registration
[difluprednate \(ophthalmic emulsion, ocular inflammation/pain\), Sirion](#)
 Therapy Area: Uveitis

[insulin \(inhaled, Technosphere\), MannKind](#)
 Therapy Area: Diabetes mellitus

Registered
[clevudine](#)
 Therapy Area: Hepatitis B virus infection

[recombinant moroctocog alfa \(plasma/albumin-free, hemophilia A\), Wyeth](#)
 Therapy Area: Factor VIII deficiency

[zolpidem \(sublingual tablet, insomnia\), Meda](#)
 Therapy Area: Insomnia

Launched
[amoxicillin \(pulsatile formulation\), MiddleBrook](#)
 Therapy Area: Pharyngitis; Tonsillitis

[Top](#) [Full results list](#)

第 1 步
Drug Phase Changes
 点击此图标进行跟踪设置
 如果使用了 Filter by Therapy Area ,您将只收到某些特定治疗领域的跟踪提醒。


SAVE EMAIL ALERT 弹出窗口

SAVE EMAIL ALERT

Send me an email when **Drug Phase Changes** is updated.

Enter a name for your alert:

Include colleagues:

Choose a folder: 

第 2 步 将跟踪保存在指定的文件夹输入)
跟踪名称 : Drug Phase Change
文件夹 : project1/Home Page Alerts
单击 **Next** 按钮

SAVE EMAIL ALERT

Send me an email when **Drug Phase Changes** is updated.

Email address

Email frequency Daily Weekly 4-Weekly

Restrict to

- Any Status
 - Discovery Research
 - All Clinical
 - Phase 1
 - Phase 2
 - Phase 3
 - Pre-Registered
 - Registered
- Launched
- Discontinued
- Suspended
- Withdrawn
- No Development Reported
- Research Tool

Notify me if zero results

第 3 步 设置跟踪条件
邮箱默认为您的注册 Email 地址，也可以进行修改。
设定您要监测的研发阶段和 Email 的频率。
点击 **Save** 按钮保存

SAVE EMAIL ALERT - Setup complete

Alert setup complete

第 4 步 跟踪设定完成！

您设置的跟踪已完成。查看您设置的跟踪，点击 **Go to folders** 按钮。

Go to folders

Cancel

电子邮件跟踪设置以下列方式送达（可设置 HTML 格式/文本格式）

发件人: Thomson Pharma by email [alerts@thomson-pharma.com]
收件人: Zhang, Hui (Scientific AP)
抄送:
主题: Home Page Alert 'Clinical Trials Watch'

THOMSON PHARMA®

EMAIL NOTIFICATION

HOME PAGE UPDATE from Thomson Pharma: Clinical Trials Watch

From Clinical Trials Watch portlet

To view all your results

[Click here](#)

跟踪提醒列出的结果

查看详细内容，点击 Click here 按钮
或点击超链接直接到达报告页面

No. of reports

LitAndNews	1
All reports	1

(Maximum of 20 displayed)

[Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas](#)

Rigel Pharmaceuticals Inc

Press Release,2009:March 13

To view all your results

[Click here](#)

**Please note: This email will expire after three months.



THOMSON REUTERS

© 2009 THOMSON REUTERS

Thomson Pharma 登录后您会看到结果列表，点击报告标题获取详细内容。

[HELP](#) [NOTICES](#) [SUPPORT](#) [TRAINING](#) [FEEDBACK](#) [LOG-OFF](#)

THOMSON PHARMA Quick Search as a Drug Name

[Home](#) | [Search Center](#) | [Browse](#) | [Personalize](#) | [Folders](#)

Process reports

[Print](#)
[Export](#)
[Send](#)
[Save](#)

Download report

[Full report PDF](#)
[Full report HTML](#)

LN Rigel Commences Phase 2...

[OVERVIEW](#) [CHEMISTRY](#)

[SUMMARY](#) [ABSTRACT](#) [EXTENDED ABSTRACT](#) [NEWS STORY](#) [FULL TEXT](#) [RELATED COMPANY NEWS](#) [COMMENTS](#) [INDEXING](#)

NEWS SUMMARY

News Title	Rigel begins phase II peripheral T-cell lymphoma trial of R-788
Original Title	Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
Source	Press Release 2009, March 13
JIF	Not Available
Authors	Rigel Pharmaceuticals Inc
Categories	Clinical trial announcements
Full text links	↔Links
Cited in Drug	fostamatinib (16-MAR-2009)

[Top](#)

NEWS STORY 1

[Rigel Pharmaceuticals](#) has begun enrollment in a phase II trial of [R-788](#) (fostamatinib) for refractory or relapsed peripheral T-cell lymphoma (PTCL). Results are expected in the second half of 2010.

In the first stage of the multicenter, North American study, 19 patients will receive 200 mg of R-788 twice daily for 8 weeks or until disease progression or withdrawal. The second part of the trial will enroll 36 patients. The primary objective is efficacy, as assessed by baseline CT/PET scans and CT scans at 8 weeks of the disease-involved areas. Safety will also be evaluated.

"Since we have seen that R-788 shows clinical therapeutic benefit in certain types of B-cell lymphomas and that Syk kinase appears to play an important role in certain PTCLs, we believe that R7-88 may offer new hope to the 12 to 15% of non-Hodgkin's lymphoma patients with the T-cell variety," said Dr Elliott Grossbard, Executive VP and CMO at Rigel [\[912576\]](#).

The drug is also in phase II trials for immune thrombocytopenic purpura and rheumatoid arthritis [\[755759\]](#), [\[688626\]](#), [\[991547\]](#).

[Top](#)

FULL TEXT 1